682 



I SAt'la oa an addition*! meeting with Dr. Abood and 

 Ots. SAttdcrs, S««Ban, and Chavdarian during Or. Abood' s last 

 visit. Z fouAd tha discussions tc b« useful and felt that 

 Dr. Abood was doing some very interesting work which can 

 ultinatel/ be of benefit to Philip Morris. I also utilized 

 Dr. Abood as a consultant during that visit and he made some 

 food suggestions and I thought the tiae was well spent. 



la suBBary, the nicotine rtceptor prograa at the • 

 Uaivarsity of Rochestar is an integral part of our overall 

 aieotiaa prograa. The combination of basic research on the 

 pharsacology of the nicotine receptor combined with the 

 capability to screen nicotine analogs for CNS activity 

 eoBpltoants our internal synthetic and behavioral efforts 

 ia the nicotine prograa. The prograa is justified la ay view 

 'as a defensive response to the anti-smoking forces criticisms 

 of nicotine and also as fundamental research into the nature 

 of our product and how It affects our ciistoacrs, th« saokers. 

 This entire prograa involve? complex technological problems 

 and the benefits to be derived from the prograa will not be 

 realized laaediately. Indeed the benefits will necessarily 

 ba of a long-tem nature and aay have direct bearing on our 

 market position in a 10-15 year time frame. However, if we 

 do not nave the basic research results this prograa will 

 provide wa will not be in a position to respond if and when 

 the pressures to change do occur. 



Ac/aro Qiy-'^^^^^ 



cc: Dr. T. S. Osdene [^ 





^ 



i 



QD 

 CI 



